Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CGIX NASDAQ:ENVB NASDAQ:GLMD NASDAQ:LIPO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGIXCancer Genetics$0.19$0.26$2.11▼$17.50$792K2.722.44 million shs19,116 shsENVBEnveric Biosciences$1.15-5.7%$1.27$1.01▼$8.95$2.84M0.46177,796 shs162,856 shsGLMDGalmed Pharmaceuticals$1.55-4.9%$1.76$1.15▼$23.80$2.56M0.58384,370 shs238,205 shsLIPOLipella Pharmaceuticals$0.71+1.3%$1.58$0.62▼$7.31$3.13M-0.08969,975 shs1,604 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGIXCancer Genetics0.00%0.00%0.00%0.00%0.00%ENVBEnveric Biosciences0.00%-12.21%-8.37%-10.85%-83.68%GLMDGalmed Pharmaceuticals0.00%-22.11%-14.13%+24.00%-57.98%LIPOLipella Pharmaceuticals0.00%+13.24%-8.97%-71.83%-89.57%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCGIXCancer GeneticsN/AN/AN/AN/AN/AN/AN/AN/AENVBEnveric Biosciences2.303 of 5 stars3.54.00.00.00.60.01.3GLMDGalmed Pharmaceuticals0.7039 of 5 stars0.02.00.00.01.42.50.6LIPOLipella Pharmaceuticals1.3185 of 5 stars0.05.00.00.00.03.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCGIXCancer Genetics 0.00N/AN/AN/AENVBEnveric Biosciences 3.00Buy$10.00769.57% UpsideGLMDGalmed Pharmaceuticals 2.00HoldN/AN/ALIPOLipella Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCGIXCancer Genetics$6.33M0.13N/AN/AN/A∞ENVBEnveric BiosciencesN/AN/AN/AN/A$2.35 per shareN/AGLMDGalmed PharmaceuticalsN/AN/AN/AN/A$9.87 per shareN/ALIPOLipella Pharmaceuticals$536.36K5.91N/AN/A$1.59 per share0.45Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCGIXCancer GeneticsN/A-$2.07N/A∞N/AN/AN/AN/AN/AENVBEnveric Biosciences-$9.57M-$38.38N/AN/AN/AN/A-250.28%-195.57%8/11/2025 (Estimated)GLMDGalmed Pharmaceuticals-$7.52M-$16.66N/A∞N/AN/A-32.21%-28.59%8/27/2025 (Estimated)LIPOLipella Pharmaceuticals-$5.02M-$4.08N/A∞N/A-988.83%-224.08%-172.88%8/12/2025 (Estimated)Latest CGIX, GLMD, ENVB, and LIPO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/22/2025Q1 2025GLMDGalmed PharmaceuticalsN/A-$0.62N/A-$0.62N/AN/A5/14/2025Q1 2025ENVBEnveric Biosciences-$3.45-$1.22+$2.23-$1.22N/AN/A5/14/2025Q1 2025LIPOLipella PharmaceuticalsN/A-$0.64N/A-$0.64N/A$0.13 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCGIXCancer GeneticsN/AN/AN/AN/AN/AENVBEnveric BiosciencesN/AN/AN/AN/AN/AGLMDGalmed PharmaceuticalsN/AN/AN/AN/AN/ALIPOLipella PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCGIXCancer GeneticsN/AN/AN/AENVBEnveric BiosciencesN/A4.084.08GLMDGalmed PharmaceuticalsN/A9.029.02LIPOLipella PharmaceuticalsN/A6.216.21Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCGIXCancer Genetics8.92%ENVBEnveric Biosciences13.82%GLMDGalmed Pharmaceuticals76.14%LIPOLipella Pharmaceuticals74.31%Insider OwnershipCompanyInsider OwnershipCGIXCancer Genetics15.00%ENVBEnveric Biosciences1.10%GLMDGalmed Pharmaceuticals19.80%LIPOLipella Pharmaceuticals32.11%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCGIXCancer GeneticsN/A4.09 millionN/ANot OptionableENVBEnveric Biosciences202.47 million2.45 millionNot OptionableGLMDGalmed Pharmaceuticals201.65 million1.33 millionNot OptionableLIPOLipella Pharmaceuticals44.47 million3.03 millionNot OptionableCGIX, GLMD, ENVB, and LIPO HeadlinesRecent News About These CompaniesLIPO - Lipella Pharmaceuticals Inc Ordinary Shares Dividends | MorningstarJuly 18, 2025 | morningstar.comMLipella Pharmaceuticals Issues Letter from the CEO to Stockholders Following Nasdaq Delisting - MorningstarJune 27, 2025 | morningstar.comMLipella Pharmaceuticals delisted from Nasdaq, explores relisting options amid ongoing operationsJune 27, 2025 | bizjournals.comLipella Pharmaceuticals Inc.: Lipella Pharmaceuticals Issues Letter from the CEO to Stockholders Following Nasdaq DelistingJune 26, 2025 | finanznachrichten.deLipella Pharmaceuticals Issues Letter from the CEO to Stockholders Following Nasdaq DelistingJune 25, 2025 | globenewswire.comNasdaq delists Lipella Pharmaceuticals over rule violationsJune 22, 2025 | investing.comLipella Pharmaceuticals Inc.: Lipella Pharmaceuticals Announces Delisting from Nasdaq Capital MarketJune 21, 2025 | finanznachrichten.deLipella stock tumbles after Nasdaq delisting over rule violationsJune 20, 2025 | in.investing.comLipella Pharmaceuticals Announces Delisting from Nasdaq Capital MarketJune 20, 2025 | globenewswire.comLipella Pharmaceuticals Inc. Announces Issuance of U.S. Patent for Advanced Detection Method of Interstitial CystitisJune 17, 2025 | quiverquant.comQLipella Pharmaceuticals Announces U.S. Patent Issuance for Diagnostic TechnologyJune 17, 2025 | globenewswire.comLipella Pharmaceuticals extends manufacturing pact with Cook MyoSiteJune 5, 2025 | investing.comLipella Re-Signs Manufacturing Collaboration Agreement with Cook MyoSiteJune 4, 2025 | contractpharma.comCLipella Pharmaceuticals Re-signs Manufacturing Collaboration Agreement with Cook MyoSite to Support LP-310 Clinical DevelopmentJune 4, 2025 | prismmediawire.comPLipella Pharmaceuticals Re-signs Manufacturing Collaboration Agreement with Cook MyoSite to Support LP-310 Clinical DevelopmentJune 4, 2025 | globenewswire.comLipella Pharmaceuticals to appeal Nasdaq noncompliance warningMay 20, 2025 | bizjournals.comLipella Pharmaceuticals to Present Phase 2a Data for LP-310 in Oral Lichen Planus at 2025 AAOM/EAOM International MeetingMay 15, 2025 | prismmediawire.comPLipella Pharmaceuticals to Present Phase 2a Data for LP-310 in Oral Lichen Planus at 2025 AAOM/EAOM International MeetingMay 15, 2025 | globenewswire.comLipella abstract on LP-10 for OLP accepted for presentation at AAOM, EAOMApril 25, 2025 | markets.businessinsider.comLipella Pharmaceuticals Inc.: Lipella Reports Positive Phase 2a Results from Second LP-310 Cohort in Oral Lichen Planus; Final Data Expected Q2 2025April 23, 2025 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCGIX, GLMD, ENVB, and LIPO Company DescriptionsCancer Genetics NASDAQ:CGIXVyant Bio, Inc. is a biotechnology company, which engages in drug discovery for complex neurodevelopmental and neurodegenerative disorders. The firm's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. Its programs are focused on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome, CDKL5 Deficiency Disorders, and familial Parkinson's Disease. The company was founded on April 8, 1999 and is headquartered in Cherry Hill, NJ.Enveric Biosciences NASDAQ:ENVB$1.15 -0.07 (-5.74%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.18 +0.04 (+3.04%) As of 08/1/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. Enveric Biosciences, Inc. is headquartered in Naples, Florida.Galmed Pharmaceuticals NASDAQ:GLMD$1.55 -0.08 (-4.91%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.53 -0.02 (-1.29%) As of 08/1/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.Lipella Pharmaceuticals NASDAQ:LIPO$0.71 +0.01 (+1.28%) As of 08/1/2025 02:53 PM EasternLipella Pharmaceuticals Inc., a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD). Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale Is PG&E an AI Power Play? Why Options Traders Are Betting Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
